Actavia Life Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RASP research report →
About the company
Actavia Life Sciences, Inc. operates as a biotechnology enterprise specializing in the development of therapeutic solutions aimed at treating various forms of leukemia and lymphoma. Additionally, the company is engaged in formulating small molecule drug candidates, with a particular emphasis on addressing acute myeloid leukemia.
- CEO
- Keeren Shah
- IPO
- 2015
- Employees
- 1
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $385.91K
- P/E
- -0.06
- P/S
- 0.00
- P/B
- -0.15
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 243.82%
- ROIC
- 242.87%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,443,000 · -546.72%
- EPS
- $-0.01 · 23.00%
- Op Income
- $-4,238,000
- FCF YoY
- 97.28%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -64.36
- Avg Volume
- 95.12
Get TickerSpark's AI analysis on RASP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RASP coverage
Recent articles, reports, and earnings notes.
No research on RASP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RASP report →Similar companies
Peers in the same neighborhood.